Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Immunex Corporation patents


Recent patent applications related to Immunex Corporation. Immunex Corporation is listed as an Agent/Assignee. Note: Immunex Corporation may have other listings under different names/spellings. We're not affiliated with Immunex Corporation, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunex Corporation-related inventors


 new patent  Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy

Improved anti-cd154 antibodies are provided herein which have improved therapeutic potency, in vivo half-life and ablated fcr binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation, transplant recipients, fibrosis and allergic disorders is disclosed herein.. ... Immunex Corporation

Use of interleukin-4 antagonists and compositions thereof

Methods for treating medical conditions induced by interleukin-4 involve administering an il-4 antagonist to a patient afflicted with such a condition. Suitable il-4 antagonists include, but are not limited to, il-4 receptors (such as a soluble human il-4 receptor), antibodies that bind il-4, antibodies that bind il-4r, il-4 muteins that bind to il-4r but do not induce a biological response, molecules that inhibit il-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of il-4 to a cell surface il-4r. ... Immunex Corporation

Beta-1,6-glucan cetuximab antibody conjugates

The present invention encompasses embodiments in which cetuximab or a related cetuximab antibody is conjugated to β-1,6-glucan oligomers. Thus, the present invention includes, among other things, compositions including cetuximab conjugated to one or more β-1,6-glucan oligomers. ... Immunex Corporation

Validating biomarker measurement

A method for validating quantification of biomarkers, the biomarkers being quantified using a quantification technique of a selected type, and the method including determining a plurality of biomarker values, each biomarker value being indicative of a value measured or derived from a measured value, for at least one corresponding biomarker of the biological subject and being at least partially indicative of a concentration of the biomarker in a sample taken from the subject, determining at least one control value by determining a combination of biomarker values, comparing each control value to a respective control reference and determining if the biomarker values are valid using results of the comparison.. . ... Immunex Corporation

Compositions and methods for cancer immunotherapy

The present invention includes, among other things, β-1,6-glucan linked to an antibody directed to a cell present in a tumor microenvironment. T regulatory cells can be one type of cell present in the tumor microenvironment. ... Immunex Corporation

Anti-human vista antibodies and use thereof

The invention provides agonistic anti-human vista antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic vista's suppressive effects on t cell immunity and thereby suppress t cell immunity. ... Immunex Corporation

Anti-human vista antibodies and use thereof

The invention provides agonistic anti-human vista antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic vista's suppressive effects on t cell immunity and thereby suppress t cell immunity. ... Immunex Corporation

Anti-human vista antibodies and use thereof

The invention provides agonistic anti-human vista antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic vista's suppressive effects on t cell immunity and thereby suppress t cell immunity. ... Immunex Corporation

Anti-human vista antibodies and use thereof

The invention provides agonistic anti-human vista antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic vista's suppressive effects on t cell immunity and thereby suppress t cell immunity. ... Immunex Corporation

Biomarker signature method, and apparatus and kits thereof

The present invention discloses methods, kits, and apparatus as well as reagents and compositions associated therewith for deriving an indicator for use in diagnosing the presence, absence or degree of at least one condition in a biological subject or in prognosing at least one condition in a biological subject. Also disclosed is a biomarker signature for use in diagnosing the presence, absence or degree of at least one condition in a biological subject or in prognosing at least one condition in a biological subject. ... Immunex Corporation

Use of interleukin-4 antagonists and compositions thereof

Methods for treating medical conditions induced by interleukin-4 involve administering an il-4 antagonist to a patient afflicted with such a condition. Suitable il-4 antagonists include, but are not limited to, il-4 receptors (such as a soluble human il-4 receptor), antibodies that bind il-4, antibodies that bind il-4r, il-4 muteins that bind to il-4r but do not induce a biological response, molecules that inhibit il-4-induced signal transduction, and other compounds that inhibit a biological effect that results from the binding of il-4 to a cell surface il-4r. ... Immunex Corporation

Use of vista agonists and antagonists to suppress or enhance humoral immunity

The present invention is directed to the use of vista agonists alone or in association with other immune inhibitors, preferably another inhibitor of humoral immunity such as an inos/no promoter or nitric oxide or a pd-1 or pd-l1 agonist or a cd40 antagonist for the treatment or prevention of conditions wherein the suppression of humoral immunity is therapeutically beneficial. The present invention is further directed to the use of vista antagonists alone or in association with other immune agonists, preferably another enhancer of humoral immunity such as inos/no inhibitor or a pd-1 or pd-l1 antagonist or anti-ctla-4 antibody or a cd40 agonist for the treatment or prevention of conditions wherein the enhancement of humoral immunity is therapeutically beneficial. ... Immunex Corporation

Soluble tumor necrosis factor receptor treatment of medical disorders

The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of tnfα by administering a tnfα antagonist, such as recombinant tnfr:fc.. . ... Immunex Corporation

Immunomodulating beta-1,6-d-glucans

This invention relates to modifications of β-1,6-d-glucans, e.g., structures according to formula (i), and the ability of these compositions to modulate an immune response.. . ... Immunex Corporation

02/23/17 / #20170051039

Compositions comprising a p75 tumor necrosis factor receptor/ig fusion protein

The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same.. . ... Immunex Corporation








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunex Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunex Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###